Lineage Cell Therapeutics, Inc.
LCTX- Exchange
- NYSE
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0000876343
No open-market purchases or sales by Lineage Cell Therapeutics, Inc. insiders were filed in the last 90 days; 131 institutions reported holding it in 13F filings for Q2 2026, worth $152.7M in total; no superinvestor holds it.
Q2 2022 vs. Q1 2022
How the institutions holding Lineage Cell Therapeutics, Inc. changed between Q1 2022 and Q2 2022.
All holders in Q2 2022All holders in Q1 2022
| Measure | Q1 2022 | Of which not filed for Q2 2022 | Q2 2022 | Change |
|---|---|---|---|---|
| Holders | 109 | 1 | 100 | −8 |
| Shares | 72.9M | 15.2K | 65.0M | −7.85M (−10.8%) |
| Value | $112.3M | $23.0K | $102.7M | −$9.63M (−8.6%) |
1 institution that held it in Q1 2022 haven't filed for Q2 2022 yet. Not filing isn't selling, so the changes leave them out.
New holders (20)
Institutions that held Lineage Cell Therapeutics, Inc. at the end of Q2 2022 but not at the end of Q1 2022.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Laurion Capital Management LP | 2,422,367 | $3.83M | 0.16% |
| Ergoteles LLC | 553,633 | $875.0K | 0.03% |
| MAI Capital Management | 247,735 | $391.0K | 0.01% |
| Qube Research & Technologies Ltd | 89,960 | $142.0K | 0.00% |
| Cubist Systematic Strategies, LLC | 88,774 | $140.0K | 0.00% |
| LMR Partners LLP | 44,733 | $71.0K | 0.00% |
| Y-Intercept (Hong Kong) Ltd | 44,829 | $71.0K | 0.01% |
| Ameriprise Financial Inc | 40,660 | $64.0K | 0.00% |
| Dowling & Yahnke LLC | 32,263 | $51.0K | 0.00% |
| Boothbay Fund Management, LLC | 27,777 | $44.0K | 0.00% |
| XTX Topco Ltd | 23,552 | $37.0K | 0.02% |
| Virtu Financial LLC | 13,380 | $21.0K | 0.00% |
| Balyasny Asset Management LLC | 10,432 | $16.0K | 0.00% |
| Tucker Asset Management LLC | 150 | $237 | 0.00% |
| Investors Asset Management of Georgia Inc | 2 | $0 | 0.00% |
| Proffitt & Goodson Inc | 17 | $0 | 0.00% |
| Capital Advisors, Ltd. LLC | 38 | $0 | 0.00% |
| Rockefeller Capital Management L.P. | 280 | $0 | 0.00% |
| Curi Capital | 51 | $0 | 0.00% |
| Newbridge Financial Services Group, Inc. | 5 | $0 | 0.00% |
Sold out (28)
Institutions that held Lineage Cell Therapeutics, Inc. at the end of Q1 2022 and filed for Q2 2022 without it.
Not filed for Q2 2022 yet (1)
Institutions that held Lineage Cell Therapeutics, Inc. at the end of Q1 2022 and haven't filed a 13F for Q2 2022. Not filing isn't selling, so they aren't counted as sold out.
| Institution | Shares, Q1 2022 | Value, Q1 2022 |
|---|---|---|
| Amalgamated Financial Corp. | 15,165 | $23.0K |